Sourcing innovation, strategically

Looking for the latest trends in biotech? Phil Gotwals has answers. In his former role focused on searching for and evaluating external science and technology at the Novartis Institutes for BioMedical Research (NIBR), he laughingly called himself a “personal shopper” for scientists looking for innovative ways to discover new medicines.

Now Head of Business Development and Licensing (BD&L) at NIBR, Gotwals is thinking more strategically. His eyes are still on the trends, but he’s also delving deeply into the science already in play at NIBR to guide thinking about which of those …

/by

Sourcing innovation, strategically

Looking for the latest trends in biotech? Phil Gotwals has answers. In his former role focused on searching for and evaluating external science and technology at the Novartis Institutes for BioMedical Research (NIBR), he laughingly called himself a “personal shopper” for scientists looking for innovative ways to discover new medicines.

Now Head of Business Development and Licensing (BD&L) at NIBR, Gotwals is thinking more strategically. His eyes are still on the trends, but he’s also delving deeply into the science already in play at NIBR to guide thinking about which of those …

/by

Novartis ligelizumab (QGE031) more effective than Xolair® at inhibiting immunoglobulin E pathway responsible for chronic spontaneous urticaria

  • Data show ligelizumab binds to immunoglobulin E (IgE), a key driver of chronic spontaneous urticaria (CSU), with significantly higher affinity than current standard of care Xolair (omalizumab)1
     
  • The study published in Nature Communications suggests ligelizumab has the potential to be more effective than Xolair in treating CSU
     
  • Earlier Phase IIb study results show more patients are completely symptom-free from CSU with ligelizumab than Xolair2
     
  • CSU is a distressing and …
/by